Estudo da relação de metabólitos da rota de degradação da adenosina com doenças cardiovasculares por meio de ferramentas quimiométricas
Data
2021-07-07
Autores
Silva, Danilo Paulo [UNIFESP]
Orientadores
Klassen, Aline [UNIFESP]
Tipo
Trabalho de conclusão de curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Resumo
As doenças cardiovasculares (DCV) são consideradas as principais causas de óbitos no mundo. O Infarto Agudo do Miocárdio (IAM) e a aterosclerose são as formas mais relevantes de cardiopatia isquêmica, sendo seu diagnóstico realizado primeiramente, pela avaliação do quadro clínico, seguido das alterações eletrocardiográficas e, por fim, análise de restritos marcadores bioquímicos cardioespecíficos. Nesse sentido, a metabolômica atrelada a quimiometria, tem ganhado cada vez mais espaço dentro da área cardiovascular, devido ao seu grande potencial no que se refere à busca de novos biomarcadores para o diagnóstico e prognóstico precoce das DCV. Dentre os metabólitos potencialmente relacionados às doenças cardiovasculares, destaca-se a adenosina. Uma elevação dos níveis de adenosina no sangue, bem como uma melhora do quadro clínico dos pacientes, por efeito dos antiplaquetários clopidogrel e ticagrelor e das estatinas sinvastatina e rosuvastatina, tem sido reportado. Entretanto, em virtude da sua elevada taxa de degradação no sangue, o estudo não somente da adenosina, mas também dos seus produtos de degradação se faz necessária. Neste contexto, o presente trabalho terá como objetivo buscar compreender a sinergia dos antiplaquetários com as estatinas, bem como o tempo de administração dos medicamentos por meio de uma avaliação quimiométrica dos níveis de adenosina e seus produtos de degradação: inosina, hipoxantina, xantina e ácido úrico, dosados no plasma de pacientes infartados. Os resultados obtidos por meio das técnicas estatísticas utilizadas neste estudo apontam que existe uma sinergia na combinação dos fármacos e os metabólitos em estudo, convergindo para uma indicação na melhoria do quadro clínico dos pacientes.
Cardiovascular diseases (CVD) are considered the main causes of death in the world. Acute Myocardial Infarction (AMI) and atherosclerosis are the most relevant forms of ischemic heart disease, the diagnosis of which is made first, by assessing the clinical picture, followed by electrocardiographic changes and, finally, analysis of restricted cardiospecific biochemical markers. In this sense, the metabolomics linked to chemometrics, has been gaining more and more space within the cardiovascular area, due to its great potential with regard to the search for new biomarkers for the diagnosis and early prognosis of CVD. Among the metabolites potentially related to cardiovascular diseases, adenosine stands out. An increase in the levels of adenosine in the blood, as well as an improvement in the clinical condition of patients, due to the effect of antiplatelet agents clopidogrel and ticagrelor and statins simvastatin and rosuvastatin, has been reported. However, due to its high rate of degradation in the blood, mo nitoring of its degradation products is necessary. In this context, the present work will aim to understand the synergy of antiplatelet drugs with statins, as well as the time of medication administration through a chemometric evaluation of adenosine level s and their breakdown products: inosine, hypoxanthine, xanthine and acid uric, dosed in the plasma of infarcted patients. The results obtained through the statistical techniques used in this study indicate that there is a synergy in the combination of drug s and metabolites under study converging to an indication for improving the clinical status of patients.
Cardiovascular diseases (CVD) are considered the main causes of death in the world. Acute Myocardial Infarction (AMI) and atherosclerosis are the most relevant forms of ischemic heart disease, the diagnosis of which is made first, by assessing the clinical picture, followed by electrocardiographic changes and, finally, analysis of restricted cardiospecific biochemical markers. In this sense, the metabolomics linked to chemometrics, has been gaining more and more space within the cardiovascular area, due to its great potential with regard to the search for new biomarkers for the diagnosis and early prognosis of CVD. Among the metabolites potentially related to cardiovascular diseases, adenosine stands out. An increase in the levels of adenosine in the blood, as well as an improvement in the clinical condition of patients, due to the effect of antiplatelet agents clopidogrel and ticagrelor and statins simvastatin and rosuvastatin, has been reported. However, due to its high rate of degradation in the blood, mo nitoring of its degradation products is necessary. In this context, the present work will aim to understand the synergy of antiplatelet drugs with statins, as well as the time of medication administration through a chemometric evaluation of adenosine level s and their breakdown products: inosine, hypoxanthine, xanthine and acid uric, dosed in the plasma of infarcted patients. The results obtained through the statistical techniques used in this study indicate that there is a synergy in the combination of drug s and metabolites under study converging to an indication for improving the clinical status of patients.